Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Disease-modifying therapie"'
Autor:
Alessandra Lugaresi, Elisa Baldin
Publikováno v:
Expert Opinion on Pharmacotherapy. 21:1955-1964
Introduction: Multiple Sclerosis (MS) is an immune-mediated, complex, chronic inflammatory, and neurodegenerative disease of the central nervous system. Among the several therapeutic options developed over the last decade for relapsing MS (RMS), fing
Autor:
Raffaele Dubbioso, Marco Bove, Daniele Boccia, Vincenzo D’Ambrosio, Maria Nolano, Fiore Manganelli, Rosa Iodice
Background Hand dexterity impairment is a key feature of disability in people with primary progressive multiple sclerosis (PPMS). So far, ocrelizumab, a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, is t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08413de70222d653b50a9675acd2f82b
http://hdl.handle.net/11588/883185
http://hdl.handle.net/11588/883185
Autor:
Gianmarco Abbadessa, Elisabetta Maida, Giuseppina Miele, Floriana Bile, Luigi Lavorgna, Simona Bonavita
Publikováno v:
Journal of Clinical Medicine. 11:6033
Siponimod, a selective modulator of sphingosine 1-phosphate receptors 1 (S1P1) and 5 (S1P5), has recently been marketed for patients with Secondary Progressive Multiple Sclerosis (SPMS). Herein, we report three SPMS patients presenting disease reacti
Autor:
Ildebrando Appollonio, Giorgia Giussani, Jacopo C. DiFrancesco, Carlo Ferrarese, Valeria Polonia, Lucio Tremolizzo, Alessandro Nobili, Carlotta Franchi, Elisa Bianchi, Ettore Beghi
Publikováno v:
Journal of Alzheimer's Disease. 60:1267-1274
Background The prevalence of epilepsy with onset in adulthood increases with age, mainly due to the accumulation of brain damage. However, a significant proportion of patients experience seizures of unknown cause. Alzheimer's disease (AD) is associat
Publikováno v:
European Journal of Internal Medicine
Highlights • Transthyretin amyloid cardiomyopathy (ATTR-AC) is an under-diagnosed disease. • Many grey areas are emerging in clinical management and prognostic stratification. • Candidates’ selection for novel drugs is crucial, but response c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78d626e622090d0ce7e1ab3c4db0a92a
https://www.sciencedirect.com/science/article/pii/S0953620520303770?via=ihub
https://www.sciencedirect.com/science/article/pii/S0953620520303770?via=ihub
Autor:
Michael Barnett, Bhim Singhal, Maria Trojano, Franco Granella, Neil Shuey, Guillermo Izquierdo, Dana Horakova, Helmut Butzkueven, Talal Al-Harbi, Maria Laura Saladino, Cameron Shaw, Adam Fambiatos, Bart Van Wijmeersch, Serkan Ozakbas, Tünde Csépány, Freek Verheul, Cavit Boz, Tim Spelman, Pierre Duquette, Jeannette Lechner-Scott, Bassem Yamout, Roberto Bergamaschi, Vincent Van Pesch, Claudio Solaro, Edgardo Cristiano, Patrizia Sola, Vilija Jokubaitis, Jae Kwan Jun, Alessandra Lugaresi, Javier Olascoaga, Aysun Soysal, Thor Petersen, Mark Slee, Raed Alroughani, Francois Grand'Maison, Orla Gray, Tomas Kalincik, Marc Girard, Gerardo Iuliano, Anneke van der Walt, Eva Havrdova, Jose Luis Sanchez-Menoyo, Radek Ampapa, Julie Prevost, Steve Vucic, Pamela A. McCombe, Recai Turkoglu, Yara Dadalti Fragoso, Jordana Hughes, Olga Skibina, Murat Terzi, Eugenio Pucci, Diana Ferraro, Pierre Grammond, Fraser Moore, Ayse Altintas, Suzanne Hodgkinson, Youssef Sidhom, Norma Deri, Alexandre Prat, Raymond Hupperts, Daniele Spitaleri, Bruce V. Taylor
Publikováno v:
Fambiatos, A, Jokubaitis, V, Horakova, D, Kubala Havrdova, E, Trojano, M, Prat, A, Girard, M, Duquette, P, Lugaresi, A, Izquierdo, G, Grand’Maison, F, Grammond, P, Sola, P, Ferraro, D, Alroughani, R, Terzi, M, Hupperts, R, Boz, C, Lechner-Scott, J, Pucci, E, Bergamaschi, R, Van Pesch, V, Ozakbas, S, Granella, F, Turkoglu, R, Iuliano, G, Spitaleri, D, McCombe, P, Solaro, C, Slee, M, Ampapa, R, Soysal, A, Petersen, T, Sanchez-Menoyo, J L, Verheul, F, Prevost, J, Sidhom, Y, Van Wijmeersch, B, Vucic, S, Cristiano, E, Saladino, M L, Deri, N, Barnett, M, Olascoaga, J, Moore, F, Skibina, O, Gray, O, Fragoso, Y, Yamout, B, Shaw, C, Singhal, B, Shuey, N, Hodgkinson, S, Altintas, A, Al-Harbi, T, Csepany, T, Taylor, B, Hughes, J, Jun, J K, van der Walt, A, Spelman, T, Butzkueven, H & Kalincik, T 2020, ' Risk of secondary progressive multiple sclerosis : A longitudinal study ', Multiple Sclerosis Journal, vol. 26, no. 1, pp. 79-90 . https://doi.org/10.1177/1352458519868990
Multiple sclerosis, Vol. 26, no. 1, p. 79-90 (2020)
Multiple sclerosis, Vol. 26, no. 1, p. 79-90 (2020)
Turkoglu, Recai/0000-0001-9724-851X; Ferraro, Diana/0000-0003-4818-3806; McCombe, Pamela/0000-0003-2704-8517; Altintas, Ayse/0000-0002-8524-5087; Jokubaitis, Vilija G./0000-0002-3942-4340; Slee, Mark/0000-0003-4323-2453; Lugaresi, Alessandra/0000-000
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12cd799ef882d65d54c9d7ef34b33e78
https://avesis.deu.edu.tr/publication/details/fb9b47c1-d816-40b5-86de-96e112b6f8f9/oai
https://avesis.deu.edu.tr/publication/details/fb9b47c1-d816-40b5-86de-96e112b6f8f9/oai
Autor:
Luigi Lavorgna, Teresa Costabile, Luca Carmisciano, R Lanzillo, N. Frattaruolo, Giacomo Lus, Alvino Bisecco, Alessio Signori, Simona Bonavita, A. Strianese, G. T. Maniscalco, V. Brescia Morra, Maddalena Sparaco, Elisabetta Signoriello, Simone Cepparulo, Francesco Saccà, Camilla Russo
Publikováno v:
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 41(11)
Background: Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS). Objective: To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) peopl
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Caterina Barrilà, Alice Laroni, Raffaella Cerqua, Giorgia Teresa Maniscalco, Alessia Di Sapio, Jessica Frau, Alessio Signori, A. Repice, Domenico Ippolito, Sara La Gioia, Giuseppe Fenu, Ignazio Roberto Zarbo, Francesco Saccà, Giorgia Mataluni, Sabrina Esposito, Elisabetta Signoriello, Arianna Sartori, Simona Bonavita, Eleonora Cocco, Roberta Lanzillo, Salvatore Lo Fermo, B. Frigeni, Valeria Barcella, Maria Pia Sormani, Simona Pontecorvo, E Binello, Pietro Annovazzi, Sarah Rasia, Cinzia Cordioli, Roberta Grasso, Valentina Torri Clerici, Damiano Baroncini, Lorena Pareja Gutierrez, Luigi Lavorgna, Marinella Clerico, Cinzia Valeria Russo, Fabio Gallo, Francesca Bovis, Silvia Rossi
Background: With many options now available, first therapy choice is challenging in multiple sclerosis (MS) and depends mainly on neurologist and patient preferences. Objectives: To identify prognostic factors for early switch after first therapy cho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee69ec79243d3027d12c7b6bcbd0a86
http://hdl.handle.net/2318/1691461
http://hdl.handle.net/2318/1691461
Autor:
Massimiliano Calabrese, Eleonora Cocco, Roberta Fantozzi, Viviana Nociti, Antonio Gallo, Laura Boffa, Alice Laroni, Claudio Solaro, Valentina Torri Clerici, Giancarlo Coghe, Simona Malucchi, Massimiliano Di Filippo, Valentina Tomassini, Marcello Moccia, Pietro Annovazzi, Federica Pinardi, Carla Tortorella, Paola Cavalla, Ilaria Pesci, Luca Prosperini, Giorgia Teresa Maniscalco, Alberto Gajofatto, Claudio Gasperini, Roberta Lanzillo, Fabio Buttari, Paolo Ragonese, Marta Radaelli, Maria Chiara Buscarinu
Publikováno v:
Journal of neurology. 265(5)
In this independent, multicenter, retrospective study, we investigated the short-term persistence to treatment with first-line self-injectable or oral disease-modifying treatments (DMTs) in patients with relapsing–remitting multiple sclerosis. Data